Details for Patent: 9,789,208

Which drugs does patent 9,789,208 protect, and when does it expire?

Patent 9,789,208 protects CYTALUX and is included in one NDA.

This patent has thirty-five patent family members in twelve countries.

Summary for Patent: 9,789,208

Title:	Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Abstract:	The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for incorporating the compounds as used for the targeted imaging of tumors. Conjugation of the amino acid linking groups increase specificity and detection of the compound. Methods and compositions for use thereof in diagnostic imaging are contemplated.
Inventor(s):	Kularatne; Sumith A. (West Lafayette, IN)
Assignee:	Purdue Research Foundation (West Lafayette, IN)
Application Number:	15/259,719
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,789,208

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
On Target Labs	CYTALUX	pafolacianine sodium	SOLUTION;INTRAVENOUS	214907-001	Nov 29, 2021		RX	Yes	Yes			Y	Y		CYTALUX IS AN OPTICAL IMAGING AGENT INDICATED IN ADULT PATIENTS WITH OVARIAN CANCER AS AN ADJUNCT FOR INTRAOPERATIVE IDENTIFICATION OF MALIGNANT LESIONS

International Family Members for US Patent 9,789,208

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013381391
Australia	2013383382
Australia	2013383386